Hamid, Omid <br/><br/>
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.  [electronic resource] 

 -  The New England journal of medicine  Jul 2013 
 - 134-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa1305133  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--administration & dosage<br/>Brain Neoplasms--secondary<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Skin Neoplasms--drug therapy